Ainos reports interim results in VELDONA trial for FCGS

Ainos (AIMD) announced interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis, a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals. The randomized, controlled trial aims to enroll 30 cats, divided into high- and low-dose treatment groups, to assess pre- and post-treatment inflammation scores, corticosteroid usage, and safety. The focus is on chronic inflammatory diseases such as feline gingivostomatitis-an area where effective long-term treatments remain limited and largely reliant on steroids.To date, three cats have completed treatment, with a fourth currently in progress. All cases have shown clear clinical improvements and strong tolerability: Case 1: Inflammation score reduced from 19 to 17; Previous treatment with a French high-dose injectable interferon treatment was ineffective; Steroid dose successfully reduced from 0.8mg/kg/day to 0.5mg/kg/day with stable condition. Case 2: Score reduced from 16 to 12.3; Steroid therapy was fully discontinued two months after treatment; condition remains stable. Case 3: Score reduced from 9 to 5; Steroids discontinued post-treatment; no relapse observed; No significant side effects were observed in any case. The results also suggest a steroid-sparing effect, which is critical for improving long-term outcomes in aging or chronically ill pets.